This investigation revealed that proton-beam resistance in drug-resistant breast cancer cells is closely correlated with the regulation of RAD51, Ku80 ad survivin. Therefore, this study suggests that a specialized strategy is required to enhance the efficacy of proton-beam therapy through targeting RAD51, Ku80 and survivin, particularly in patients exhibiting chemoresistance.